骨改良药治疗骨转移的研究进展  

Research progress of bone-modifying agents in the treatment of bone metastases

作　　者：孙姗姗[1] 张月蒙 高英杰[1] 高文仓[1] 

机构地区：[1]大连大学附属新华医院肿瘤内科,116021

出　　处：《国际肿瘤学杂志》2014年第3期226-228,共3页Journal of International Oncology

摘　　要：骨改良药是一类缓解因骨转移引起的疼痛、病理性骨折、脊髓压迫、高钙血症等一系列骨相关事件药物的总称。目前主要有双膦酸盐类药物和地诺单抗。骨改良药应用于证实有骨质破坏的骨转移患者，作为化疗、放疗的辅助用药，可以明显提高疗效，延长患者的生存期。此外，中医中药也可以有效缓解骨转移引起的一系列相关症状，改善预后。临床工作中要选择合理的药物，才能最大限度地降低骨转移患者的痛苦，提高生活质量。Bone-modifying agents （BMA） is a series drugs to alleviate the pain, pathological fractures, spinal cord compression, hypercalcemia, bone-related events which induced by bone metastases. Bisphosphonate drugs and denosumab are two dominant kinds of BMA at present. It has been proved that BMA is used in bone metastases patients with bone destruction, as adjuvant therapy for chemotherapy and radiotherapy, which can significantly improve the efficacy and prolong the survival of patients. In addition, some traditional Chinese medcine can effectively relieve a series of related symptoms caused by bone metastases and improve prognosis. Choosing right medication in clinical work can maximize the reduction of pain caused by bonerelated events and improve the quality of life of patients.

关 键 词：肿瘤转移 二膦酸盐类 地诺单抗 

分 类 号：R730.5[医药卫生—肿瘤]